GSK And Oxford To Collaborate On Neoantigen Vaccines To Prevent Cancer

 
• By Andrew McConaghie

The potentially groundbreaking approach would use immunotherapy or targeted therapies against pre-cancerous cells to prevent cancer from developing at all.

Oxford, UK
GSK is extending its existing relationship with the University of Oxford, home to world-class academic biomedical research. • Source: Shutterstock

More from R&D

More from Business